Department of Neurosurgery and Pediatric Neurosurgery, Medical University of Lublin, Jaczewskiego 8, 20-954 Lublin, Poland.
Department of Immunology, Medical University of Lublin, Chodźki 4a, 20-093 Lublin, Poland.
Int J Mol Sci. 2020 Feb 22;21(4):1507. doi: 10.3390/ijms21041507.
Based on genome sequencing, it is estimated that over 90% of genes stored in human genetic material are transcribed, but only 3% of them contain the information needed for the production of body proteins. This group also includes micro RNAs representing about 1%-3% of the human genome. Recent studies confirmed the hypothesis that targeting molecules called Immune Checkpoint (IC) open new opportunities to take control over glioblastoma multiforme (GBM). Detection of markers that indicate the presence of the cancer occupies a very important place in modern oncology. This function can be performed by both the cancer cells themselves as well as their components and other substances detected in the patients' bodies. Efforts have been made for many years to find a suitable marker useful in the diagnosis and monitoring of gliomas, including glioblastoma.
基于基因组测序，据估计，人类遗传物质中储存的超过 90%的基因都被转录，但其中只有 3%的基因包含产生身体蛋白质所需的信息。这组基因还包括约占人类基因组 1%-3%的 microRNAs。最近的研究证实了这样一种假设，即针对被称为免疫检查点 (IC) 的靶向分子可以为控制多形性胶质母细胞瘤 (GBM) 开辟新的机会。检测表明癌症存在的标志物在现代肿瘤学中占有非常重要的地位。这种功能既可以由癌细胞本身，也可以由其成分以及在患者体内检测到的其他物质来完成。多年来，人们一直在努力寻找一种在诊断和监测包括胶质母细胞瘤在内的神经胶质瘤中有用的合适标志物。
